Sep 20th, 2022
Late-Breaking Science announced
See the impressive lineup of Late-Breaking Science on tap for presentation in Chicago.
LBS.01. Late-Breaking Science: The Main Event: Changing Clinical Practice
Saturday, Nov. 5 | 9:30-10:30 a.m. | Main Event I
- Comparative Effectiveness of Torsemide Versus Furosemide in Heart Failure: Primary Results of the TRANSFORM-HF Trial (TRANSFORM-HF)
- Chlorthalidone Compared to Hydrochlorothiazide for the Prevention of Cardiovascular Events in Patients With Hypertension (DCP)
- A Randomized Trial of Pemafibrate for Triglyceride Reduction in the Prevention of Cardiovascular Disease (PROMINENT)
LBS.02. Late-Breaking Science: Breakthrough Strategies in the HF Journey
Saturday, Nov. 5 | 3-4 p.m. / Main Event I
- First-in-Human in vivo CRISPR/Cas9 Editing of the Ttr Gene by Ntla-2001 in Patients With Transthyretin Amyloidosis With Cardiomyopathy
- A Patient-Risk Based Health System Intervention for Acute Heart Failure Care: The Comparison of Outcomes and Access to Care for Heart Failure (COACH) Trial (COACH Trial)
- Early Results of the Patient-Reported Outcome Measurement in Heart Failure Clinic (PRO-HF) Trial (PRO-HF)
- IRONMAN: A Randomized Trial of Intravenous Ferric Derisomaltose in Heart Failure With Reduced Ejection Fraction (IRONMAN)
LBS.03. Late-Breaking Science: High Impact Trials in Intervention and Surgery
Sunday, Nov. 6 | 8-9 a.m. | Main Event I
- Radial Artery Patency and Clinical Outcomes (RAPCO) Randomized Trials—The 15-Year Clinical Outcomes Comparing Radial Artery With Right Internal Thoracic Artery or With Saphenous Vein Grafting (RAPCO)
- Steroids to Reduce Systemic Inflammation After Infant Heart Surgery: The Stress Trial (STRESS Trial)
- The Impact of Chinese Herbal Medicine, Tongxinluo in Patients With Acute Myocardial Infarction—Results From the CTS-AMI Trial (CTS-AMI)
- Extracorporeal Membrane Oxygenation in the Therapy of Cardiogenic Shock: Primary Results From the Multicenter, Randomized ECMO-CS Trial (ECMO-CS)
LBS.04. Late-Breaking Science: Mindful Disruption of Chronic HTN Management
Sunday, Nov. 6 | 3:30-4:30 p.m. | Main Event I
- Effectiveness of a Village Doctor-Led Multifaceted Implementation Strategy on Cardiovascular Disease Among Patients With Hypertension: A Cluster Randomized Trial (CRHCP)
- Reducing Inequities in Care of Hypertension: Lifestyle Improvement for Everyone: Blood Pressure and Patient-Reported Outcomes (The Rich Life Project)
- The Effect of Adapted Mindfulness Training in Participants With Elevated Office Blood Pressure: The Mindfulness-Based Blood Pressure Reduction (MB-BP) Randomized Clinical Trial (The MB-BP Study)
- Efficacy and Safety of a Quadruple Ultra-Low-Dose Treatment for Hypertension (QUARTET USA): A Randomized Controlled Trial (QUARTET USA)
LBS.05. Late-Breaking Science: Changing How We Prevent Cardiovascular and Renal Disease
Sunday, Nov. 6 | 5-6 p.m. | Main Event I
- Randomized Trial for Evaluating Secondary Prevention Efficacy of Combination Therapy—Statin and Eicosapentaenoic Acid (RESPECT-EPA)
- Reduction of Lipoprotein(a) With Small Interfering RNA: The Results of the Ocean(a)-DOSE Trial (OCEAN(a) DOSE)
- Empagliflozin and Cardiovascular Outcomes in Patients With Chronic Kidney Disease: The EMPA-KIDNEY Trial (EMPA-KIDNEY)
- Effect of Low-Dose Statin Compared With Placebo and Six Dietary Supplements on Lipid and Inflammatory Biomarkers: The SPORT Randomized Clinical Trial (SPORT)
LBS.06. Late-Breaking Science: Drugs and Strategies in ACS and Revascularization
Sunday, Nov. 6 | 5-6 p.m. | Main Event II
- Bivalirudin With a Post-PCI High-Dose Infusion Versus Heparin Monotherapy During Primary PCI in Stemi: The Randomized Bright-4 Trial (BRIGHT-4)
- Efficacy and Safety of Indobufen Versus Aspirin After Coronary Drug-Eluting Stent Implantation: A Randomized, Open-Label, Non-Inferiority Trial (OPTION)
- Comparison of a Precision Care Strategy With Usual Testing to Guide Management of Stable Patients With Suspected Coronary Artery Disease: The Precise Randomized Trial (PRECISE)
- ISCHEMIA-EXTENDed Follow-Up Interim Report (ISCHEMIA-EXTENDed)
LBS.07. Late-Breaking Science: Preventing Limb Loss Through Vascular Interventions and Venous Therapies
Monday, Nov. 7 | 8-9 a.m. | Main Event I
- Best Endovascular Versus Best Surgical Therapy for Patients With Chronic Limb Threatening Ischemia (BEST-CLI) Trial: Clinical Results (BEST-CLI)
- Best Endovascular Versus Best Surgical Therapy for Patients With Chronic Limb Threatening Ischemia (BEST-CLI) Trial: Quality of Life Analyses (BEST-CLI)
- Rivaroxaban to Reduce the Risk of Major Venous and Arterial Thrombotic Events, Hospitalization and Death in Medically Ill Outpatients With COVID-19: Primary Results of the PREVENT-HD Randomized Clinical Trial (PREVENT-HD)
- A Multicenter Clustered Randomized Trial of a Universal Electronic Health Record-Based Venous Thromboembolism Risk Assessment Model as Integrated Clinical Decision Support for Prevention of Thromboembolism in Hospitalized Medically Ill Patients (IMPROVE Trial)
LBS.08. Late-Breaking Science: Treating Atrial and Supraventricular Arrhythmias
Monday, Nov. 7 | 11 a.m.-Noon | Main Event I
- The Impact of “First-Line” Rhythm Therapy on Atrial Fibrillation Progression: The Progressive-AF Trial (PROGRESSIVE-AF)
- Self-Administered Etripamil for Termination of Spontaneous Paroxysmal Supraventricular Tachycardia: Primary Analysis From the Rapid Study (RAPID)
- Efficacy and Safety of Botulinum Toxin Type A for the Prevention of Postoperative Atrial Fibrillation in Cardiac Surgery Patients: Results From the Phase 2 Nova Study (NOVA)
- Clinical Trial to Evaluate an Atrial Fibrillation Stroke Prevention Shared Decision-Making Pathway (ENHANCE-AF)
LBS.09. Late-Breaking Science 9: Resistant HTN: A Pressure Cooker
Monday, Nov. 7 | 3-4 p.m. | Main Event I
- Top-Line Results of The First-in-Class Aminopeptidase-A Inhibitor Firibastat in Treatment-Resistant Hypertension (FRESH) Study (FRESH)
- Sustained Blood Pressure Lowering Effect With the Dual Endothelin Receptor Antagonist Aprocitentan in Resistant Hypertension: Results From a Randomized, Controlled Study Including a Withdrawal Phase (PRECISION)
- Results From a Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Baxdrostat in Patients With Treatment-Resistant Hypertension (BrigHTN)
- Effect of Radiofrequency Renal Denervation on Blood Pressure in the Presence of Antihypertensive Drugs: 6-Month Primary Results From the SPYRAL HTN-ON Med Expansion Randomized Trial (SPYRAL HTN-ON)
Featured Science Sessions
FS.01. In-Depth and Fresh Look in Heart Failure Trials
Sunday, Nov. 6 | 8-9 a.m.
- The Effect of Percutaneous Revascularization on Arrhythmic Risk in Ischemic Left Ventricular Dysfunction (REVIVED-BCIS2)
- Natriuretic Response With Acetazolamide in Acute Heart Failure With Volume Overload: Analysis From the ADVOR Trial (ADVOR)
- Decongestion With Acetazolamide in Acute Decompensated Heart Failure Across the Spectrum of Left Ventricular Ejection Fraction: A Pre-Specified Analysis From the Advor Trial (ADVOR)
- Empagliflozin and Cardiac Remodeling in People Without Diabetes: Primary Results of EMPA-HEART 2 CardioLink-7 Randomized Placebo-Controlled Trial (EMPA-HEART 2)
- First and Repeat Episodes of Worsening Heart Failure in Patients With Heart Failure With Mildly Reduced and Preserved Ejection Fraction: An Analysis of Deliver (DELIVER)
FS.02. New Insights — Cardiac Surgery
Sunday, Nov. 6 | 9:30 -10:30 a.m.
- Myosin Inhibition in Patients With Obstructive HCM Referred for Septal Reduction Therapy: 32-Week Active Blinded Crossover Results From Valor-HCM Trial (VALOR-HCM)
- Electrocardiographic Changes After Cardiac Surgery and 30-Day Mortality (VISION Cardiac Surgery)
- Interim Results of a Phase 2 Study With RBT-1 Evaluating Postoperative Course in Patients Undergoing Elective CABG/Valve Surgery on Cardiopulmonary Bypass (The START Study)
- Results From the Clinical Implementation of Partial Oral Treatment of Patients With Infectious Endocarditis; A Nationwide Study. Time for Poetry?
FS.03. Featured Science in Heart Rhythm Medicine
Sunday, Nov. 6 | 5-6 p.m.
- Feasibility and Safety of Intravenous Sotalol Administered as a Loading Dose to Initiate Oral Sotalol Therapy in Adult Patients With Atrial Fibrillation - DASH AF Study (DASH-AF)
- Subcutaneous Implantable Cardioverter-Defibrillator System Post Approval Study: Primary Results (S-ICD PAS)
- Apixaban or Vitamin K Antagonists for Stroke Prevention in Patients With Atrial Fibrillation on Hemodialysis: Results of the Randomized Axadia-AFNET 8 Trial (AXADIA-AFNET 8)
- Association of Genetic Risk and Outcomes in Patients With Early Rhythm Control Therapy in Atrial Fibrillation: Results From the East-afnet4 Study (EAST-AFNET4)
FS.04. Emerging Heart Failure Science
Monday, Nov. 7 | 8-9 a.m.
- Safety and Efficacy of Non-Ischemic Hypothermic Machine Perfusion (NIHP) in Human Heart Transplantation With an Ischemic Time of 6-8 Hours
- A Randomized, Multicenter, Placebo-Controlled Trial of the Beta3 Adrenergic Agonist, Mirabegron on Left Ventricular Mass and Diastolic Function in Patients With Structural Heart Disease, the Beta3lvh Trial (BETA3LVH)
- The Prelieve Trial: Final 1-Year Outcomes of the Prospective Atrial Flow Regulator Study in Heart Failure Patients and Responder Analysis (Prelieve)
- Exercise for the Prevention of Anthracycline-Induced Functional Disability and Cardiac Dysfunction: The Breast Cancer Exercise Intervention (BREXIT) Study (BREXIT)
- Dissemination of a Decision Support Tool for Left Ventricular Assist Device: How a Majority of United States Programs Implemented I-DECIDE-LVAD into Standard Patient Evaluations (I-DECIDE-LVAD)
- STRONG-HF: Successful Post-Discharge Management of Heart Failure
FS.05. Evolving Science in COVID-19
Monday, Nov. 7 | 8-9 a.m.
- Anti-c5a Vilobelimab Reduces All-Cause Mortality in Critically Ill Covid-19 Patients and in Those With Comorbid Hypertension: A Phase 3 Randomized Double-Blind, Placebo-Controlled Study (PANAMO)
- A Randomized Trial of Lipid Metabolism Modulation With Fenofibrate for Acute Coronavirus Disease 2019 (FERMIN)
- Impact of Coronavirus Disease-2019 on Participants in Deliver (DELIVER)
- Rare Coding Variants in Cardiomyopathy-Associated Genes Predispose to Severe Covid-19 and Cardiac Injury (COVID-CARDOGEN)
- Prevalence of Myocarditis Among Patients Hospitalized With Laboratory-Confirmed SARS-CoV-2 Infection―14 US States, March 2020-May 2022 (COVID-NET)
FS.06. Optimal Management Post PCI/ACS
Monday, Nov. | 9:30-10:30 a.m.
- Long-Term Outcomes of an Invasive versus Conservative Strategy in Stabilised Patients Aged 80 Years or Older With Non-ST-Elevation Acute Coronary Syndrome, After Eighty Study: A Randomised Controlled Trial (After Eighty Study)
- Long-Term Follow-Up of Aspirin vs. Clopidogrel Monotherapy in the Chronic Maintenance Period After Percutaneous Coronary Intervention: The Host-Exam Extended Study
- Impact of Ticagrelor With or Without Aspirin on Total and Recurrent Bleeding and Ischemic Events After PCI: Results From the Twilight - Recurrent Events Sub-Study (TWILIGHT)
- Effect of Semaglutide on Progression of Coronary Atherosclerosis in Patients With Type 2 Diabetes: Final Results of the Stop Study (STOP)
FS.07. A Second Look at Practice-Changing Heart Failure Trials
Monday, Nov. 7 | 11 a.m.-Noon
- The Effects of Dapagliflozin on Symptoms, Function and Quality of Life in Patients With Heart Failure and Mildly Reduced or Preserved Ejection Fraction: Results From the DELIVER Trial (DELIVER)
- Baseline Characteristics, Outcomes, and Treatment Response to Dapagliflozin in Patients Treated With an MRA or ARNI in DELIVER (DELIVER)
- Sex Differences in Characteristics, Outcomes and Treatment Response With Dapagliflozin Across the Range of Ejection Fraction in Patients With Heart Failure (DAPA-HF, DELIVER)
- Differences in Clinical Characteristics, Outcomes, and Treatment Response to Dapagliflozin Across the Range of Ejection Fraction in Black and White Patients With Heart Failure: A Pooled Analysis of DAPA-HF and Deliver (DAPA-HF, DELIVER)
- Comparison of Clinical Outcomes and Efficacy of Empagliflozin in Black vs White Patients With Heart Failure: A Pooled Analysis From the EMPEROR Program (EMPEROR-Pooled)
- Long-Term Survival After Cardiac Resynchronization in Ambulatory Heart Failure (RAFT)
FS.08. Digital Innovations to Improve CVD Prevention
Monday, Nov. 7 | 11 a.m.-Noon
- Randomized, Controlled Trial of Digital Nutritional Cognitive Behavioral Therapy in Patients With Type 2 Diabetes Mellitus: Primary Outcomes of the BT-001 Pivotal Trial at 180 Days (BT001 PIVOTAL) - Accepted, Not Confirmed
- A Randomized Controlled Trial of a Remotely Delivered Mobile Health Intervention to Augment Cardiac Rehabilitation: The Virtual AppLication-Supported ENvironment To INcrease Exercise (VALENTINE) Study (The VALENTINE Study)
- Smartphone-Based Cardiovascular Risk Reduction in Breast Cancer Patients [Smart-Breast]: A Randomized Controlled Trial (SMART-BREAST)
- A PRagmatic Trial Of Messaging to Providers About Treatment of HyperLIPIDemia (PROMPT-LIPID)
- Incidental Coronary Artery Calcium: Opportunistic Screening of Prior Non-Gated Chest CTs to Improve Statin Rates (NOTIFY-1) - Accepted, Not Confirmed
FS.09. The Present and Future of Lipid Lowering
Monday, Nov. 7 | 3-4 p.m.
- ARO-ANG3, an Investigational RNAi Therapeutic, Decreases Serum Angiopoietin-Like Protein 3, Triglycerides, and Cholesterol in Patients With Mixed Dyslipidemia (ARCHES-2)
- ARO-APOC3, an Investigational RNAi Therapeutic, Decreases Serum Apolipoprotein C3, Triglyceride, and Non-HDL-C Concentrations While Increasing HDL-C in Patients With Severe Hypertriglyceridemia (SHASTA-2)
- Long-Term Efficacy of Very Low LDL-Cholesterol Levels With the PCSK9 Inhibitor Evolocumab: Analysis of the FOURIER and FOURIER-OLE Studies (FOURIER-OLE)
- Efficacy and Safety of Twice-Yearly Subcutaneous Inclisiran in Patients With High Cardiovascular Risk and Elevated Low-Density Lipoprotein Cholesterol up to 4 Years-The Orion-3 Trial
- Individual Participant Data Meta-Analysis of New-Onset and Worsening Diabetes Mellitus in Large-Scale Randomized Double-Blind Trials of Statin Therapy
Learn more about Late-Breaking Science and other Featured Sessions by visiting the Online Program Planner.
